Immunome Expands Workforce to Enhance Cancer Therapy Development and Drug Pipeline

Immunome Expands Talent Pool to Propel Cancer Therapy Development

Immunome, Inc., a biotechnology firm based in Bothell, Washington, focuses on developing innovative therapies targeting cancer. The company recently announces the granting of inducement awards to four new employees, reflecting its commitment to enhancing its workforce as it advances its innovative drug pipeline. Under the 2024 Inducement Plan, these awards consist of non-statutory stock options totaling 45,000 shares of common stock, each priced at $10.53, which aligns with the company's closing share price on January 2, 2025. The stock options will vest over four years, with an initial 25% vesting on the one-year anniversary of the grant date, followed by monthly vesting of the remaining shares contingent upon ongoing service.

This strategic move is part of Immunome's broader strategy to bolster its experienced leadership team, which is crucial for the development of its advanced targeted cancer therapies. The company emphasizes its commitment to improving patient outcomes through first-in-class and best-in-class therapies. The addition of new talent is expected to enhance the company’s capabilities in research and development, particularly as Immunome works on a robust pipeline of investigational new drug applications. With significant progress being made, the company aims to file INDs for two investigational agents, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radioligand, by the first quarter of 2025.

Immunome's flagship candidate, AL102, is currently in a Phase 3 trial for desmoid tumors, showcasing the company's ongoing commitment to targeted cancer therapies. The firm’s leadership, which has a track record of developing advanced antibody-drug conjugates, plays a pivotal role in navigating the complex landscape of drug development. As Immunome continues to expand its talent pool and accelerate its pipeline, the company remains focused on its mission to deliver innovative therapies that improve cancer patient outcomes.

In addition to its talent expansion, Immunome remains vigilant about the potential risks and uncertainties surrounding its pipeline and regulatory timelines. The company's forward-looking statements regarding its development plans are contingent on various factors that could impact actual results. As such, Immunome actively monitors these developments to align its strategic objectives with the evolving landscape of cancer therapy.

With its strong emphasis on innovation and expanding its workforce, Immunome is positioning itself as a key player in the biotechnology sector, dedicated to advancing cancer care through targeted therapies. For more information about the company’s initiatives, visit www.immunome.com.